Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | BMP1 | P13497 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18646647 | 0.83 | MAPT (0.39) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL20414883 | 0.76 | CA2 (0.44) | MAPK1 | |
| SCHEMBL13445989 | 0.76 | MMP2 (0.31) | BMP1 | |
| SCHEMBL13351183 | 0.76 | CA2 (0.44) | MAPK1 | |
| SCHEMBL13267743 | 0.75 | USP2 (0.44) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL25556371 | 0.75 | MMP1 (0.40) | BMP1 | |
| SCHEMBL17377402 | 0.75 | MMP3 (0.44) | — | |
| SCHEMBL13267748 | 0.74 | USP2 (0.47) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL25139537 | 0.73 | MMP3 (0.34) | BMP1 | |
| SCHEMBL7980257 | 0.73 | SIRT6 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140371148-A1 | PEPTIDE-PEPTIDASE INHIBITOR CONJUGATES AND METHODS OF USING SAME | ASTRAZENECA PHARMACEUTICALS LP | 2014-12-18 | — | — | US | disclosed |
| US-8759295-B2 | Peptide-peptidase inhibitor conjugates and methods of using same | AMYLIN PHARMACEUTICALS, LLC (US) | 2014-06-24 | — | — | US | disclosed |
| US-20100292172-A1 | Peptide-Peptidase Inhibitor Conjugates and Methods of Using Same | AMYLIN PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100286365-A1 | PEPTIDE-PEPTIDASE-INHIBITOR CONJUGATES AND METHODS OF MAKING AND USING SAME | AMYLIN PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | US | disclosed |
| US-20090186817-A1 | PEPTIDE-PEPTIDASE INHIBITOR CONJUGATES AND METHODS OF USING SAME | AMYLIN PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292172-A1 | Peptide-Peptidase Inhibitor Conjugates and Methods of Using Same | DNPEP, PEPD, VIP | CYP1A2 4169/4885CYP2D6 3890/4885MAPT 3716/4885 |
| US-20090186817-A1 | PEPTIDE-PEPTIDASE INHIBITOR CONJUGATES AND METHODS OF USING SAME | DNPEP, PEPD, VIP | CYP1A2 4169/4885CYP2D6 3890/4885MAPT 3716/4885 |
| US-20140371148-A1 | PEPTIDE-PEPTIDASE INHIBITOR CONJUGATES AND METHODS OF USING SAME | DNPEP, PEPD, VIP | CYP1A2 4169/4885CYP2D6 3890/4885MAPT 3716/4885 |
| US-20100286365-A1 | PEPTIDE-PEPTIDASE-INHIBITOR CONJUGATES AND METHODS OF MAKING AND USING SAME | DNPEP, PEPD, VIP | CYP1A2 4059/4885CYP2D6 3593/4885MAPT 3789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.